KONVOMEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KONVOMEP (KONVOMEP).
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
| Metabolism | Fosnetupitant: Converted to netupitant by alkaline phosphatase; netupitant metabolized via CYP3A4. Palonosetron: Partially metabolized by CYP2D6, CYP3A4, and CYP1A2. |
| Excretion | Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible. |
| Half-life | Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | 98-99% bound to albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.3 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral: 60-80% (first-pass metabolism reduces from absolute bioavailability of 100% for IV). |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; Intravenous: 12 hours. Clinical effect persists for dosing interval. |
| Molecular Weight | 787.73 |
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) due to lack of data. |
| Liver impairment | No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid use in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients ≥65 years with no overall differences in safety or efficacy. |
| 1st trimester | No adequate studies in pregnant women; use only if potential benefit justifies risk to fetus. Animal studies show no teratogenicity at clinically relevant doses. |
| 2nd trimester | No evidence of fetal harm in animal studies; human data limited. Caution advised. |
| 3rd trimester | Potential for adverse effects on fetal gastric acid suppression; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for KONVOMEP (KONVOMEP).
| Placental transfer | Not studied in humans; based on molecular weight and high protein binding, placental transfer is likely limited but not negligible. |
| Breastfeeding | Excretion in human milk unknown; caution due to potential for adverse effects in nursing infants, especially gastric acid suppression. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to vonoprazan or any component of the formulationConcomitant use with atazanavir or rilpivirine (reduced absorption due to gastric pH increase)
| Precautions | Hypersensitivity reactions (including anaphylaxis, hypotension, and dyspnea) have been reported with palonosetron., Serotonin syndrome may occur with co-administration of serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs)., Netupitant is a moderate CYP3A4 inhibitor; avoid concurrent use with strong CYP3A4 substrates (e.g., pimozide) and reduce dose of certain CYP3A4 substrates (e.g., midazolam)., Constipation and diarrhea may occur. |
| Food/Dietary | Avoid alcohol as it may worsen headache or increase risk of stomach bleeding. No specific food restrictions, but take with food if gastrointestinal upset occurs. Grapefruit juice may alter naproxen metabolism; limit intake. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Konvomep (esomeprazole) is a proton pump inhibitor. In animal studies, no evidence of teratogenicity was observed at doses up to 57 times the human dose. Human data from large cohort studies do not indicate an increased risk of major congenital malformations after use in the first trimester. However, there is limited data on use in later trimesters. Fetal risk cannot be excluded, but available evidence suggests low risk. |
| Fetal Monitoring | Monitor maternal hemoglobin and iron stores due to potential for reduced iron absorption with long-term PPI use. No specific fetal monitoring required for esomeprazole use alone, but standard prenatal monitoring should be continued. |
| Fertility Effects | Animal studies showed no impairment of fertility at esomeprazole doses up to 57 times the human dose. Human data on fertility effects are lacking. No significant impact on fertility is expected based on available evidence. |
| Clinical Pearls | KONVOMEP is a combination of sumatriptan and naproxen sodium. Administer at the first sign of migraine for optimal efficacy. Do not exceed 2 tablets in 24 hours. Use with caution in patients with cardiovascular risk factors due to sumatriptan's vasoconstrictive effects. Naproxen component increases bleeding risk, especially with anticoagulants or NSAIDs. For patients with renal impairment, monitor creatinine and avoid if CrCl <30 mL/min. |
| Patient Advice | Take one tablet at the first sign of a migraine headache. Do not take more than 2 tablets in 24 hours. · Do not use this medication if you have a history of heart disease, stroke, or uncontrolled high blood pressure. · Avoid taking other NSAIDs (like ibuprofen or aspirin) or triptans while using KONVOMEP. · Seek emergency medical help if you experience chest pain, shortness of breath, or sudden weakness on one side of the body. · If no relief after the first dose, do not take a second dose; consult your healthcare provider. |